From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Over the past decades, an emerging role of phosphates in the pathogenesis of hematologic malignancies and solid tumors has been established. The tumor suppressor Protein phosphatase 2A (PP2A) belongs to the serine-threonine phosphatases family and accounts for the majority of serine-threonine phosphatase activity in eukaryotic cells. Numerous studies have shown that inhibition of PP2A expression and/or function contributes to disengage kinases and impairs the balance between kinases and phosphatases activities. Interestingly, in some cases unrestrained oncogene kinases suppresses PP2A activity, thus promoting a feed-back loop which further allows unrestrained kinase activity. Likewise, overexpression or aberrant expression of physiologic PP2A inhibitory molecules (e.g. SET and its associated SETBP1 and CIP2A) may turn off PP2A function and participate to leukemic progression. In chronic myeloid leukemia PP2A down-regulation seems to be a hallmark feature of leukemic hematopoietic progenitor and stem cells. Likewise, PP2A loss-of-function seems to confer poor prognosis also in many other myeloid and lymphoid malignancies. The discovery of PP2A as tumor suppressor has prompted the evaluation of the safety and the efficacy of new compounds which can restore PP2A activity in leukemic cells. Albeit further studies are needed to better understand how PP2A acts in the intricate phosphatases/kinases cancer network, the results reviewed herein strongly support the development on new PP2A activating drugs (PADs) and the immediate introduction of those available into clinical protocols for leukemia patients refractory or resistant to current available therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 1×
“pS62-Myc is more stable than its dephosphorylated counterpart, and CIP2A therefore prevents c-Myc degradation (35).”
BackgroundProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
Self-citationPP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 1×
“In addition to the tumorsuppressors TP53, RB1, and ATM, usually lost in several leukemias, inhibition of specific phosphatases expression or loss of their function has been recently detected in many cancers (3).”
BackgroundAho, T. L. T., Sandholm, J., Peltola, K. J., Mankonen, H. P., Lilly, M., & Koskinen, P. J. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.06.050 · Cited by 325
Calin, G. A., di Iasio, M. G., Caprini, E., Vorechovsky, I., Natali, P. G., Sozzi, G., Croce, C. M., Barbanti-Brodano, G., Russo, G., & Negrini, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203389 · Cited by 219
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · cited 1×
“Likewise, CIP2A have been found overexpressed in hematological malignancies and in solid tumors, and to be associated with high proliferation rate and poor prognosis (46, 47).”
BackgroundLucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0292 · Cited by 130
Cited by
Ruvolo, P. P. (2016) · BBA Clinical · doi:10.1016/j.bbacli.2016.08.002 · Cited by 143
Meeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“A nice example of the effectiveness of such a strategy in a pre-clinical setting is the benefit of combining PP2A activators (PADs) and tyrosine kinase inhibitors (TKIs) in hematologic malignancies characterized by nongenetically inhibited PP2A (628, 658-661).”
BackgroundConditional knockout in mice reveals the critical roles of Ppp2ca in epidermis development
Fang, C., Li, L., & Li, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050756 · Cited by 15
Metadata
- Authors
- Ciccone, M., Calin, G. A., & Perrotti, D.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2015-02-16
- Volume
- 5
- Pages
- 21-21
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1965418027
- Cited by
- 63
- References
- 10
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. https://app.cochat.ai/papers/10.3389/fonc.2015.00021
- The paper
- Ciccone, M., Calin, G. A., & Perrotti, D. (2015). From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. Frontiers in Oncology. https://doi.org/10.3389/fonc.2015.00021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.